Potential role of immunoablation and hematopoietic cell transplantation in the treatment of early diabetes type 1.
Immunoablation with autologous hematopoietic cell transplantation has shown some effectiveness in the treatment of autoimmune diseases as diverse as aplastic anemia, systemic lupus erythematosus, multiple sclerosis and Crohn's disease. It has been recently shown that this treatment might prevent or delay development of diabetes type 1. The majority of more than 30 patients with early diabetes type 1 who underwent immunoablation and hematopoietic cell transplantation in various centers in the world achieved durable remission of diabetes and independence of exogenous insulin. This review summarizes advantages and risks of this treatment of early diabetes type 1.
Snarski
Emilian
E
Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland. esnarski@amwaw.edu.pl
Milczarczyk
Alicja
A
Franek
Edward
E
Jedrzejczak
Wieslaw
W
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*
D007166:Immunosuppressive Agents